Business Wire

SES: Notification of the Acquisition or Disposal of Major Holdings

Jaa

ANNEXE A

Form to be used for the purposes of notifying the acquisition or disposal of major holdings pursuant to the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities (referred to as “the Transparency Law” and “the Transparency Regulation”)

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached1: SES SA

2. Reason for the notification (please tick the appropriate box or boxes):

[X] an acquisition or disposal of voting rights

[ ] an acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

[ ] an event changing the breakdown of voting rights

3. Full name of person(s) subject to the notification obligation2:

Lazard Asset Management LLC

4. Full name of shareholder(s) (if different from the person mentioned in point 3.)3:

5. Date of the transaction and date on which the threshold is crossed or reached4:

October 31, 2017

6. Threshold(s) that is/are crossed or reached:

5%

7. Notified details:

A) Voting rights attached to shares (article 8 and 9 of the Transparency Law)
Categories/type of shares (if possible using the ISIN CODE)   Situation previous to the triggering transaction5 Please refer to the situation disclosed in the previous notification. In case the situation previous to the triggering transaction was below the lowest applicable threshold of 5%, please state “below minimum threshold”.  

Resulting situation after the triggering transaction6 If the holding has fallen below the lowest applicable threshold of 5%, please note that it is not necessary to disclose the extent of the holding, only that the new holding is below that minimum threshold.

For the case provided for in article 9(a) of the Transparency Law, there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an article 8 threshold. This applies upon entering into, introducing changes to or terminating an agreement.

Number of voting rights7 Direct and indirect. Number of voting rights8 In case of combined holdings of shares with voting rights attached “direct holding” and voting rights “indirect holding”, please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.   % of voting rights9 The result of the division should be rounded to 2 decimal places.
Direct10 Voting rights attached to shares held by the notifying party (article 8 of the Transparency Law).   Indirect11 Voting rights held by the notifying party independently of any holding of shares (article 9 of the Transparency Law). Direct   Indirect
LU0088087324 25,881,537   31,480,357   5.47%
      -   -
TOTAL (all categories, based on aggregate voting rights)

25,881,537

31,480,357

5.47%

B) Financial Instruments (article 12 of the Transparency Law)
Resulting situation after the triggering transaction12 If the holding has fallen below the lowest applicable threshold of 5%, please note that it is not necessary to disclose the extent of the holding, only that the new holding is below that minimum threshold.
Type of financial instrument   Expiration Date13 Date of maturity/expiration of the financial instrument, i.e. the date when right to acquire shares ends.   Exercise/Conversion Period/Date14 If the financial instrument has such a period – please specify this period – for example once every 3 months starting from [date].   Number of voting rights that may be acquired if the instrument is exercised/converted   % of voting rights that may be obtained if the instrument is exercised/converted15 The result of the division should be rounded to 2 decimal places.
         
         
TOTAL (in relation to all expiration dates, all categories)    

8. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable16:

Lazard Asset Management LLC has the ability to exercise the voting rights of 25,881,537 shares, on behalf of its clients.

9. In case of proxy voting: [name of the proxy holder] will cease to hold [number] voting rights as of [date].

10. Additional information:

Done at 30 Rockefeller Plaza, New York NY, 10112 on November 6, 2017.

1 Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.

2 This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in article 9(b) to (h) of the Transparency Law; (c) all the parties to the agreement referred to in article 9(a) of that Law, or (d) the holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate.

In relation to the transactions referred to in letters (b) to (h) of article 9 of the Transparency Law, the following list is provided as indication of the persons who should be mentioned;

- in the circumstances foreseen in letter (b) of article 9 of the Transparency Law, the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

- in the circumstances foreseen in letter (c) of article 9 of the Transparency Law, the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

- in the circumstances foreseen in letter (d) of article 9 of the Transparency Law, the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

- in the circumstances foreseen in letter (e) of article 9 of the Transparency Law, the controlling natural person or legal entity and, provided it has a notification duty at an individual level under article 8 or letters (a) to (d) of article 9 of that Law, the controlled undertaking;

- in the circumstances foreseen in letter (f) of article 9 of the Transparency Law, the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

- in the circumstances foreseen in letter (g) of article 9 of the Transparency Law, the natural person or legal entity that controls the voting rights;

- in the circumstances foreseen in letter (h) of article 9 of the Transparency Law, the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion.

3 Applicable in the cases provided for in article 9(b) to (h) of the Transparency Law. This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in article 9 of the Law unless the percentage of voting rights held by the shareholder is lower than 5%.

4 The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect. For passive crossings, the date when the corporate event took effect.

5 Please refer to the situation disclosed in the previous notification. In case the situation previous to the triggering transaction was below the lowest applicable threshold of 5%, please state “below minimum threshold”.

6 If the holding has fallen below the lowest applicable threshold of 5%, please note that it is not necessary to disclose the extent of the holding, only that the new holding is below that minimum threshold.

For the case provided for in article 9(a) of the Transparency Law, there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an article 8 threshold. This applies upon entering into, introducing changes to or terminating an agreement.

7 Direct and indirect.

8 In case of combined holdings of shares with voting rights attached “direct holding” and voting rights “indirect holding”, please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

9 The result of the division should be rounded to 2 decimal places.

10 Voting rights attached to shares held by the notifying party (article 8 of the Transparency Law).

11 Voting rights held by the notifying party independently of any holding of shares (article 9 of the Transparency Law).

12 If the holding has fallen below the lowest applicable threshold of 5%, please note that it is not necessary to disclose the extent of the holding, only that the new holding is below that minimum threshold.

13 Date of maturity/expiration of the financial instrument, i.e. the date when right to acquire shares ends.

14 If the financial instrument has such a period – please specify this period – for example once every 3 months starting from [date].

15 The result of the division should be rounded to 2 decimal places.

16 The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds a percentage of voting rights equivalent to or higher than the lowest applicable threshold of 5%, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking.

Contact information

SES
Pierre Margue
Legal Services Corporate and Finance
Tel. +352 710 725 276
Pierre.margue@ses.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 16:33Tiedote

Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for

MIPI Alliance Opens Access to its MIPI I3C Sensor Interface Specification12.12.2017 16:00Tiedote

The MIPI® Alliance, an international organization that develops interface specifications for mobile and mobile-influenced industries, today announced it is opening access to its sensor interface specification, MIPI I3C. Starting today, all companies, including those not currently members of MIPI Alliance, may access the MIPI I3C v1.0 specification so they may evaluate the incorporation of the specification into their sensor integration plans and design applications. “MIPI I3C provides a welcome update to the I2C technology that has been widely adopted over the past 35 years. Extending access provides an opportunity to spur innovation and help other industries beyond mobile," said Joel Huloux, chairman of MIPI Alliance. "It helps MIPI members as well, because it supports greater adoption and interoperability, strengthens the ecosystem and provides for a richer

CTS Engines Announces Senior Management Hire12.12.2017 16:00Tiedote

CTS Engines, the global leader for mature jet engine maintenance, announced today that it had hired Diane E. Cavuoto as Senior Vice President, Supply Chain, in an effort to continue to provide its customers with outstanding engine overhaul services. Ms. Cavuoto will be based in CTS’s Ft. Lauderdale headquarters and will report directly to Vesa Paukkeri, CTS’s President and Chief Operating Officer. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005050/en/ Diane E. Cavuoto, Senior Vice President, Supply Chain, for CTS Engines (Photo: Business Wire) Ms. Cavuoto, most recently Vice President, Strategic Sourcing at Honeywell International, brings years of supply chain management experience to CTS. In her prior role at Honeywell, Ms. Cavuoto managed a global commodity team of 150 employees managing $4

LTI to Offer Blockchain Solution Powered by Microsoft Azure12.12.2017 13:45Tiedote

Larsen & Toubro Infotech Ltd. (NSE: LTI, BSE: 540005), a global technology consulting and digital solutions company, announced today the availability of its blockchain-based trade finance solution on Microsoft Azure marketplace. The solution tracks the flow of goods in a value chain, improving transparency across multiple entities involved. It enables accelerated adoption of distributed ledger technologies by bringing together LTI’s deep industry knowledge and blockchain capabilities together with Microsoft’s expertise in cloud-based solutions. Aftab Ullah, Chief Operating Officer, LTI said, "Our vision is to deliver exponential operational efficiencies to the world’s leading companies through digital innovation. LTI’s Blockchain services include end-to-end consulting and implementation and are designed to help transform our clients’ business operations. The collaboration

Munich Re Automation Solutions Ltd. today announced the launch of their latest data analytics and reporting product, ALLFINANZ Insight12.12.2017 12:06Tiedote

Munich Re Automation Solutions Ltd., the leading provider of digital underwriting solutions to the life insurance industry, today announced the launch of their latest data analytics and reporting product, ALLFINANZ Insight. ALLFINANZ Insight is designed to help life insurance companies unlock the insights hidden in their underwriting data using a creative and intuitive interface and 30 years of underwriting expertise built in. A vast amount of data is captured during the new business and underwriting process. Accurately categorising and understanding this data can be hugely valuable as the insights generated will significantly improve the design of underwriting rules, the new business and underwriting process as well as operations and distribution management. ALLFINANZ Insight gives your whole team a clearer, deeper view into their underwriting data. The software uses cutt

New Data for Darzalex®▼(daratumumab) Presented at ASH 2017 Show Feasibility of Subcutaneous Use and Potential of Darzalex as a Treatment for Smouldering Multiple Myeloma12.12.2017 11:00Tiedote

Janssen-Cilag International NV (“Janssen”) today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of Darzalex® (daratumumab) co-formulated with recombinant human hyaluronidase enzyme (daratumumab-SC), was generally well-tolerated, with a 12 percent rate of infusion-related reactions (IRRs), in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta. Daratumumab is currently approved for intravenous (IV) administration, and results from the PAVO trial serve as the basis for an actively enrolling Phase 3 study comparing subcutaneous administration of daratumumab over 3-5 minutes with the approved IV administration in relapsed and refractory multiple myeloma patients.2 Daratumumab is currently indica

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme